Analyst Expectations for Acrivon Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Acrivon Therapeutics (NASDAQ:ACRV) within the last quarter. These 4 analysts have an average price target of $22.5 versus the current price of Acrivon Therapeutics at $8.78, implying upside. This average price target has increased by 7.14% over the past month.
October 05, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have provided bullish ratings for Acrivon Therapeutics, with an average price target of $22.5, implying upside from the current price.
The bullish ratings from analysts and the higher price target compared to the current price suggest a positive short-term impact on Acrivon Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100